Flomoxef Triethylamine, EvoPure is the triethylamine salt of Flomoxef, a β-lactam antibiotic, an oxa-1 cephamycin belonging to the oxacephem group. It has broad-spectrum activity against Gram-negative and Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA). Flomoxef was synthesized in 1982 by Shionogi & Co, Osaka, Japan.
Unlike Latamoxef, it has [1-(2-hydroxethyl)-1H-tetrazol-5'yl] thiomethyl (HTT) as a side chain at the 3'-position of the cephem group instead of NMTT, and it also has a modification of 7 beta-amino side chain.
The compound is commonly used as a reference standard.
We also offer:
| Mechanism of Action | Flomoxef is a β-lactam inhibitor that acts by inhibiting cell-wall synthesis. This is performed by binding to penicillin-binding protein via competitive inhibition. This prevents the formation of an antibiotic-inhibitor complex thus preventing the transpeptidation step of peptidoglycan synthesis in bacterial cell walls, leading to the inhibition of cell-wall biosynthesis. |
| Spectrum | Flomoxef has broad-spectrum activity against Gram-negative and Gram-positive bacteria including methicillin-resistant Staphylocccus aureus (MRSA). It is also active against Nocardia.. |
| Microbiology Applications | Flomoxef is commonly used in clinical in vitro microbiological antimicrobial susceptibility tests (panels, discs, and MIC strips) against Gram-positive and Gram-negative microbial isolates. Medical microbiologists use AST results to recommend antibiotic treatment options. Representative MIC values include:
For a representative list of Flomoxef MIC values, click here. |
| Molecular Formula | C21H33F2N7O7S2 |
|
Cazzola M et al (1993) Flomoxef, a new oxacephem antibiotic, does not cause hemostatic defects. Int. J. Clin. Pharmacol. Ther. Toxicol. 31(3):148-152 PMID 8468113 Gilman AG, Rall TW, and Nies AS (eds) (1990) Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed. Macmillan Publishing Co, New York, NY Ito M and Ishigami T (1991) The meaning of the development of Flomoxef and clinical experience in Japan. Infection 19 (suppl 5):S253-S257 PMID 1783441 Kitahara T et al (2004) Antimicrobial activity of saturated fatty acids and fatty amines against Methicillin-resistant Staphylococcus aureus. Biol. Pharm. Bull. 27(9):1321-1326 PMID 15340213 Ruckdeschel G and Eder W (1988) Comparative in vitro activity of the new oxacephem antibiotic, Flomoxef. Eur. J. Clin. Microbiol. Infect. Dis. 7:687-691 PMID 3143586 Simon C, Simon M and Plieth C et al (1988) In vitro activity of Flomoxef in comparison to other cephalosporins. Infection 16(2):131-4 PMID 3372024 Tsuji T, Satoh H, Narisada M, Hamashima Y and Yoshida T (1985) Synthesis and antibacterial activity of 6315-S, a new member of the oxacephem antibiotic. J. Antibiotics 38 (4):466-476 PMID 4008339 Yazawa K, Mikami Y, Uno J, Otozai K, Arai T (1989) In-vitro activity of Flomoxef, a new oxacephem group antibiotic, against Nocardia in comparison with other cephalosporins. J. Antimicrob. Chemother. 24(6):921-925 PMID 2621177 |
